Novalgin® (Tablets) Instructions for Use
ATC Code
N02BE51 (Paracetamol in combination with other drugs, excluding psycholeptics)
Active Substances
Caffeine (Ph.Eur. European Pharmacopoeia)
Paracetamol (Rec.INN WHO registered)
Propyphenazone (Rec.INN WHO registered)
Clinical-Pharmacological Group
Combination analgesic-antipyretic
Pharmacotherapeutic Group
Analgesics; other analgesics and antipyretics; anilides
Pharmacological Action
A combined medicinal product. The combination of the three components of the drug leads to a mutual enhancement of their pharmacological action.
Paracetamol and Propyphenazone have analgesic and antipyretic effects. Paracetamol is a non-narcotic analgesic. It blocks COX only in the CNS, affecting the centers of pain and thermoregulation (in inflamed tissues, cellular peroxidases neutralize the effect of paracetamol on COX), which explains the almost complete absence of an anti-inflammatory effect. The lack of effect on the synthesis of prostaglandins (PG) in peripheral tissues determines the absence of a negative effect on water-salt metabolism (sodium and water retention) and the gastrointestinal mucosa.
Propyphenazone is a pyrazolone derivative. The mechanism of action is carried out by inhibiting COX, which is involved in the formation of prostaglandins from arachidonic acid.
Caffeine increases the reflex excitability of the spinal cord, excites the respiratory and vasomotor centers, dilates the blood vessels of skeletal muscles, brain, heart, kidneys, reduces platelet aggregation; reduces drowsiness, feeling of fatigue. In this combination, Caffeine in a small dose has practically no stimulating effect on the CNS, but contributes to the regulation of cerebral vascular tone, reduces drowsiness, and enhances the analgesic effect of other components of the drug.
Pharmacokinetics
Paracetamol
Absorption is high, plasma protein binding is 15%, Tmax is 20-30 min. Penetrates the BBB. Less than 1% of the dose taken by a nursing mother penetrates into breast milk. The therapeutic effective concentration of paracetamol in plasma is achieved when it is prescribed at a dose of 10-15 mg/kg.
Metabolized in the liver: 80% undergoes a conjugation reaction with glucuronic and sulfuric acids to form inactive metabolites; 17% undergoes hydroxylation to form inactive metabolites, which conjugate with glutathione and form inactive metabolites. With a lack of glutathione, these metabolites can block the enzyme systems of hepatocytes and cause their necrosis. T1/2 is 2-3 hours. In elderly patients, the clearance of paracetamol decreases and the half-life increases. Excreted by the kidneys unchanged 3%.
Propyphenazone
Cmax of propyphenazone in plasma is reached after 30 min. Metabolized in the liver. T1/2 is 1-1.5 hours. Combination with paracetamol increases its elimination time by 40%, which plays a significant role, as it allows to reduce the number of drug doses per day. Excreted by the kidneys.
Caffeine
Time to reach Cmax – 1 hour; T1/2 – 3.5 hours; 65-80% of caffeine is excreted by the kidneys mainly in the form of 1-methylxanthine, 1-methyluric acid and acetylated uracil derivatives, a small amount is converted to theophylline and theobromine.
Indications
Relief of mild to moderate pain of various origins: headache; migraine; toothache; arthralgia; myalgia; algodysmenorrhea.
As an antipyretic for febrile conditions against the background of infectious and inflammatory diseases (ARVI, including influenza, etc.).
ICD codes
| ICD-10 code | Indication |
| G43 | Migraine |
| J06.9 | Acute upper respiratory infection, unspecified |
| J10 | Influenza due to identified seasonal influenza virus |
| K08.8 | Other specified disorders of teeth and supporting structures (including toothache) |
| M25.5 | Pain in joint |
| M79.1 | Myalgia |
| N94.4 | Primary dysmenorrhea |
| N94.5 | Secondary dysmenorrhea |
| R50 | Fever of unknown origin |
| R51 | Headache |
| R52.0 | Acute pain |
| R52.2 | Other chronic pain |
| ICD-11 code | Indication |
| 1E30 | Influenza due to identified seasonal influenza virus |
| 8A80.Z | Migraine, unspecified |
| 8A8Z | Headache disorders, unspecified |
| CA07.0 | Acute upper respiratory tract infection of unspecified site |
| DA0A.Z | Diseases of teeth and supporting structures, unspecified |
| FB56.2 | Myalgia |
| GA34.3 | Dysmenorrhea |
| LA30.5Z | Anomalies of tooth resorption or loss, unspecified |
| ME82 | Pain in joint |
| MG26 | Fever of other or unknown origin |
| MG30.Z | Chronic pain syndrome, unspecified |
| MG31.Z | Acute pain, unspecified |
Dosage Regimen
| The method of application and dosage regimen for a specific drug depend on its form of release and other factors. The optimal dosage regimen is determined by the doctor. It is necessary to strictly adhere to the compliance of the dosage form of a specific drug with the indications for use and dosage regimen. |
Take tablets orally, after meals, with a small amount of liquid.
For adults, administer 1-2 tablets up to 4 times a day as needed for pain or fever.
Do not exceed a maximum daily dose of 6 tablets.
For children aged 12 to 18 years, administer 1 tablet up to three times a day.
Limit the duration of use to no more than 3 days for antipyretic purposes.
Limit the duration of use to no more than 5 days for analgesic purposes.
Do not use in children under 12 years of age.
Use with caution in elderly patients and adjust dosage if necessary.
If symptoms persist beyond the recommended treatment duration, consult a physician for re-evaluation.
Avoid concomitant use with other products containing paracetamol or caffeine to prevent overdose.
Adverse Reactions
From the nervous system dizziness, insomnia.
From the gastrointestinal tract nausea, vomiting, heaviness and discomfort in the stomach area;
From the hematopoietic system thrombocytopenia, agranulocytosis, hemolytic anemia.
Allergic reactions skin rash, itching, urticaria, angioedema, multiforme exudative erythema (including Stevens-Johnson syndrome), toxic epidermal necrolysis (Lyell’s syndrome).
Contraindications
Hypersensitivity to the components of the drug; severe renal and/or hepatic insufficiency; deficiency of the enzyme glucose-6-phosphate dehydrogenase; inhibition of bone marrow hematopoiesis (leukopenia, anemia, including hemolytic); acute hematoporphyria; complete or incomplete combination of bronchial asthma, recurrent polyposis of the nose and paranasal sinuses and intolerance to NSAIDs (including history); conditions accompanied by respiratory depression; intracranial hypertension; acute myocardial infarction; coronary artery disease; arrhythmias; arterial hypertension; peptic ulcer of the stomach and duodenum; glaucoma; insomnia; pregnancy; lactation; children under 12 years of age.
With caution benign hyperbilirubinemia (including Gilbert’s syndrome, Dubin-Johnson syndrome, Rotor syndrome), old age, alcoholism, epilepsy and a tendency to convulsive seizures.
Use in Pregnancy and Lactation
Contraindicated during pregnancy and lactation (breastfeeding).
Use in Hepatic Impairment
Contraindicated in severe hepatic insufficiency.
Use in Renal Impairment
Contraindicated in severe renal insufficiency.
Pediatric Use
Contraindication: children under 12 years of age.
Geriatric Use
With caution: old age.
Special Precautions
With long-term use (more than 5 days), monitoring of the peripheral blood picture and the functional state of the liver is necessary.
During treatment, one should refrain from consuming alcoholic beverages (increased risk of gastrointestinal bleeding).
Excessive consumption of caffeine-containing products (coffee, tea) during treatment may cause overdose symptoms.
Taking the drug may complicate the diagnosis in acute abdominal pain syndrome.
Effect on ability to drive vehicles and mechanisms
During the reception, caution should be exercised when driving vehicles and engaging in other activities that require increased concentration and speed of psychomotor reactions.
Drug Interactions
The effectiveness of this combination may decrease with simultaneous use with cholestyramine, anticholinergics, antidepressants, alkaline substances.
With simultaneous use with barbiturates, anticonvulsants, ethanol, the hepatotoxic effect is significantly increased.
Metoclopramide accelerates the absorption of paracetamol.
Under the influence of paracetamol, the half-life of chloramphenicol increases by 5 times.
Simultaneous use of paracetamol in high doses enhances the effect of anticoagulants.
Myelotoxic agents enhance the manifestations of hematotoxicity of paracetamol.
Caffeine accelerates the absorption of ergotamine; reduces the absorption of calcium preparations; reduces the effect of narcotic and hypnotic drugs, increases the excretion of lithium preparations; accelerates the absorption and enhances the effect of cardiac glycosides, increases their toxicity.
Simultaneous use of caffeine with beta-blockers may lead to mutual suppression of therapeutic effects, with beta-agonists to additional stimulation of the CNS and other toxic effects.
Caffeine may reduce the clearance of theophylline, and possibly other xanthines, increasing the possibility of additive pharmacodynamic and other toxic effects.
MAO inhibitors, furazolidone, procarbazine, selegiline and large doses of caffeine may cause the development of dangerous cardiac arrhythmias or a marked increase in blood pressure.
Nicotine increases the rate of caffeine excretion.
Caffeine is an antagonist of adenosine.
Propyphenazone may enhance the effect of oral hypolipidemic agents, sulfonamide drugs, anticoagulants, the ulcerogenic effect of glucocorticosteroids, reduces the effectiveness of potassium-sparing diuretics.
Storage Conditions
Store at 2°C (36°F) to 25°C (77°F). Keep in original packaging, protected from light. Keep out of reach of children.
Dispensing Status
Over-the-Counter
Important Safety Information
This information is for educational purposes only and does not replace professional medical advice. Always consult your doctor before use. Dosage and side effects may vary. Use only as prescribed.
Medical DisclaimerBrand (or Active Substance), Marketing Authorisation Holder, Dosage Form
Tablets 200 mg+200 mg+50 mg: 6, 12, 24, or 30 pcs.
Marketing Authorization Holder
Alvils Patent, LLC (Russia)
Manufactured By
Styrolbiopharm LLC (Ukraine)
Dosage Form
| Novalgin® | Tablets 200 mg+200 mg+50 mg: 6, 12, 24, or 30 pcs. |
Dosage Form, Packaging, and Composition
| Tablets | 1 tab. |
| Paracetamol | 200 mg |
| Propyphenazone | 200 mg |
| Caffeine | 50 mg |
6 pcs. – blisters (1) – cardboard packs.
12 pcs. – blisters (1) – cardboard packs.
12 pcs. – blisters (2) – cardboard packs.
30 pcs. – polymer containers (1) – cardboard packs.
Tablets 50 mg+200 mg+200 mg: 6, 10, 12, 20, 24, 30, 48, or 60 pcs.
Marketing Authorization Holder
Alvils, LLC (Russia)
Manufactured By
Ozon, LLC (Russia)
Dosage Form
| Novalgin® | Tablets 50 mg+200 mg+200 mg: 6, 10, 12, 20, 24, 30, 48, or 60 pcs. |
Dosage Form, Packaging, and Composition
Tablets from white to white with a yellowish tint, round, flat-cylindrical, with a score on one side and bevels on both sides; marbling is allowed.
| 1 tab. | |
| Caffeine | 50 mg |
| Paracetamol | 200 mg |
| Propyphenazone | 200 mg |
Excipients: microcrystalline cellulose – 100 mg, croscarmellose sodium – 8 mg, sodium starch glycolate (type A) – 44.8 mg, povidone K25 – 18 mg, colloidal silicon dioxide – 3.2 mg, magnesium stearate – 16 mg.
6 pcs. – contour cell packs (1) – cardboard packs.
6 pcs. – contour cell packs (2) – cardboard packs.
10 pcs. – contour cell packs (1) – cardboard packs.
10 pcs. – contour cell packs (2) – cardboard packs.
12 pcs. – contour cell packs (1) – cardboard packs.
12 pcs. – contour cell packs (2) – cardboard packs.
24 pcs. – contour cell packs (1) – cardboard packs.
24 pcs. – contour cell packs (2) – cardboard packs.
30 pcs. – jars (1) – cardboard packs.
60 pcs. – jars (1) – cardboard packs.
